Long-standing efforts to develop drugs that target MEKs could soon come to fruition, moving the frontier to how best to combine them with other cancer therapies.
Rights and permissions
About this article
Cite this article
Opar, A. New class of kinase inhibitors poised to join the anticancer arsenal. Nat Rev Drug Discov 11, 819–820 (2012). https://doi.org/10.1038/nrd3880
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3880
- Springer Nature Limited